Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease

Refractory and/or Relapsing Cryptococcosis Associated with Acquired Immune Deficiency Syndrome: Clinical Features, Genotype, and Virulence Factors of Cryptococcus spp. Isolates

(2016) Erika Nascimento et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013)

(2016) Mariana Castanheira et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Molecular epidemiology andin vitroantifungal susceptibility testing of 108 clinicalCryptococcus neoformans sensu latoandCryptococcus gattii sensu latoisolates from Denmark

(2016) Ferry Hagen et al.   MYCOSES

ANTIFUNGAL SUSCEPTIBILITY TESTING AND GENOTYPING CHARACTERIZATION OF Cryptococcus neoformans AND gattii ISOLATES FROM HIV-INFECTED PATIENTS OF RIBEIRÃO PRETO, SÃO PAULO, BRAZIL

(2016) Thais Pandini FIGUEIREDO et al.   REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO

Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda

(2015) Kyle D. Smith et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Response to therapy in patients with cryptococcosis and AIDS: Association with in vitro susceptibility to fluconazole

(2015) Carlos Andrés Agudelo et al.   REVISTA IBEROAMERICANA DE MICOLOGIA

Comparison of Etests and Vitek 2® to broth microdilution for the susceptibility testing of Cryptococcus neoformans

(2014) Yesholata Mahabeer et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Azole Heteroresistance in Cryptococcus neoformans: Emergence of Resistant Clones with Chromosomal Disomy in the Mouse Brain during Fluconazole Treatment

(2013) Edward Sionov et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment

(2013) F. P. Gullo et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Amphotericin B and Flucytosine

(2012) A. Espinel-Ingroff et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Fluconazole, Itraconazole, Posaconazole, and Voriconazole

(2012) A. Espinel-Ingroff et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Correlation of antifungal susceptibility and molecular type within theCryptococcus neoformans/C. gattiispecies complex

(2012) Luciana Trilles et al.   MEDICAL MYCOLOGY

Comparative Analysis of the Vitek 2 Antifungal Susceptibility System and E-test with the CLSI M27-A3 Broth Microdilution Method for Susceptibility Testing of Indian Clinical Isolates of Cryptococcus neoformans

(2012) Aarti Tewari et al.   MYCOPATHOLOGIA

Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America

(2010) John R. Perfect et al.   CLINICAL INFECTIOUS DISEASES